[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531246":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":40,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":40,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":40,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":44,"whyStopped":40,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Mackay Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Solifenacin with vaginal estrogen cream","EXPERIMENTAL","Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.",[13],"Drug: Solifenacin with vaginal estrogen cream",{"label":15,"type":16,"description":17,"interventionNames":18},"Combination pharmacotherapy","ACTIVE_COMPARATOR","Combined solifenacin 5mg and mirabegron 25mg once per day.",[19],"Drug: Combination pharmacotherapy",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg",[9],[26],"Premarin",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Solifenacin 5mg and Mirabegron 25mg",[15],[31],"Vesicare and Betmiga",[33],{"name":34,"affiliation":5,"role":35},"Hui-Hsuan Lau, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","+886-2-25433535",null,"huihsuan1220@gmail.com",[43],{"facility":5,"status":44,"city":45,"state":40,"zip":40,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Taipei","Taiwan","TW",{"type":49,"coordinates":50},"Point",[51,52],121.52639,25.05306,{"lat":52,"lon":51},[55],{"name":56,"role":38,"phone":57,"phoneExt":40,"email":58},"Jiun Chyi Hwang, MD","+886-2-2543-3535","jiun1989@gmail.com",{"type":35,"investigatorFullName":34,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Head of urogynecology, Associate Professor","100531246","phase-4-efficacy-of-combined-pharmacotherapy-versus-solifenacin-with-vaginal-estrogen-cream-for-women-with-detrusor-overactivity-100531246",false,"NCT06197295","Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","Efficacy and Safety of Solifenacin Combined With Mirabegron Versus Solifenacin With Vaginal Estrogen Cream for the Treatment of Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.\n* Women who were on hormone replacement therapy within 3 months were also excluded from the study","FEMALE","40 Years","90 Years",{"count":72,"type":73},200,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.",[79,80],"Urinary Bladder, Overactive","Effect of Drug",[82,83,84,85],"Detrusor overactivity","Combined pharmacotherapy","Estrogens","Effectiveness","2025-05-06",{"date":88,"type":89},"2025-05-09","ACTUAL",{"date":91,"type":89},"2022-06-16",{"date":93,"type":73},"2026-12-31",{"name":5,"class":6},1]